• April 24, 2023

    Adcentrx Therapeutics Announces Completion of $38 million Series A+ Financing Led by Eight Roads Ventures



    January 13,2023


    Please Join ABio-X CEO Jeff Jonas and various industry experts on Wednesday, January 18th, from 2 to 3 p.m. ET as we look at what’s to come for the biotech sector in 2023. Take a look at some of the questions we’ll be debating below: 
    • Will pharmaceutical companies take a more active role in dealmaking? 
    • What clinical trial readouts could shape R&D investments?
    • Will demand for IPOs bounce back?
    ABio-X:Overview | LinkedIn

    April 28, 2021

    Adcentrx Therapeutics Announces Completion of $50M Series A Financing Led By CBC Group To Accelerate Next-Generation Conjugate Drugs Research & Development.

    Read more



    April 6, 2022

    ENSEM Therapeutics is proud to announce our Series A funding of $67 million to further advance our Kinetic EnsembleTM platform and accelerate R&D pipeline.

    Read more 

    February 14, 2022

    Adcentrx and AvantGen Enter a New Partnership with a Three-year, Multi-target Collaboration to Discover Antibodies for Novel Antibody-drug Conjugates
  • November 10, 2022

    CBC-backed ABio-X appoints pharmaceutical and healthcare veteran Dr. Jeffrey Jonas as CEO